10 results about "Coliphage" patented technology

The invention relates to the technical field of microorganisms, in particular to an escherichia coli bacteriophage for improving the antibacterial effect of cecropin and application of the escherichia coli bacteriophage. The bacteriophage is named as RDP-EC-22139, the genome of the bacteriophage does not contain virulence genes and lyogenicity related genes, and the bacteriophage has good biological safety. The bacteriophage has relatively strong lysis activity on drug-resistant pathogenic escherichia coli, can still keep stable lysis titer in a relatively wide temperature and pH condition range, and has good genetic stability. When the bacteriophage is combined with cecropin for use, the minimum inhibitory concentration of the cecropin on drug-resistant pathogenic escherichia coli is remarkably reduced, the minimum inhibitory concentration can be reduced to 1 / 2-1 / 8 of the minimum inhibitory concentration when the cecropin is independently used, the inhibition time on pathogenic bacteria is remarkably prolonged, and a stable and unexpected synergistic antibacterial effect is shown. The invention provides a safe and effective biological technical scheme for prevention and control of drug-resistant Escherichia coli infection, and has a good application prospect.

The application belongs to the technical field of bioengineering, and particularly relates to a bacteriophage PE-2 of Escherichia coli with high blood entry efficiency and fermentation efficiency and application. The bacteriophage involved in the application has a preservation number of CCTCC NO: M20252973, and can specifically lyse pathogenic Escherichia coli O2 serotype and has high blood entry efficiency. The bacteriophage can enter blood circulation through oral administration, and can be widely distributed to the spleen, liver, heart and other tissues through blood circulation. The bacteriophage can be prepared in pilot production to obtain a very high titer, and the titer reaches 1.6x10 12 PFU / mL. Compared with the production of antibiotics, the production cost of the bacteriophage is low, and the bacteriophage provides a source and a reference example for industrial production of high-titer bacteriophage.

The invention discloses an Escherichia coli bacteriophage D9, a bacteriophage composition and application thereof, the preservation number of the Escherichia coli bacteriophage D9 is CGMCC (China General Microbiological Culture Collection Center) NO. 46365, and the Escherichia coli bacteriophage D9 is preserved in China General Microbiological Culture Collection Center on January 2, 2025, and the preservation address is No.3, No.1 Yard, Beichen West Road, Chaoyang District, Beijing. The bacteriophage composition comprises an escherichia coli bacteriophage D9 and other bacteriophages. The coliphage D9 has better high-temperature resistance and acid resistance, is high in breeding speed, is suitable for industrial production, has excellent splitting performance on multiple strains of multi-drug-resistant clinical escherichia coli, can be used as an active ingredient of a biological bactericide, a pharmaceutical preparation or a disinfectant, and has a wide application prospect. The compound is applied to the aspects of sterilization, bacteriostasis and disinfection of multi-drug-resistant escherichia coli, treatment or prevention of infectious diseases caused by escherichia coli and the like.

The invention discloses an Escherichia coli bacteriophage D5, a bacteriophage composition and application thereof, the preservation number of the Escherichia coli bacteriophage D5 is CGMCC (China General Microbiological Culture Collection Center) NO. 46364, and the Escherichia coli bacteriophage D5 is preserved in China General Microbiological Culture Collection Center on January 2, 2025, and the preservation address is No.3, No.1 Yard, Beichen West Road, Chaoyang District, Beijing. The bacteriophage composition comprises an escherichia coli bacteriophage D5 and other bacteriophages. The Escherichia coli phage D5 has good high temperature resistance and acid resistance, the environmental tolerance enables the Escherichia coli phage D5 to keep high activity and stability and high breeding speed in industrial production, and the Escherichia coli phage D5 is suitable for industrial production and supports rapid proliferation and large-scale fermentation production requirements; the compound has excellent splitting performance on multiple strains of multi-drug-resistant clinical escherichia coli, can be used as an active ingredient of a biological bactericide, a medicinal preparation or a disinfectant, and is applied to the aspects of sterilization, bacteriostasis and disinfection of the multi-drug-resistant escherichia coli, treatment or prevention of infectious diseases caused by the escherichia coli and the like.

The application discloses an Aeromonas phage recombinant system, an expression vector, a recombinant strain and application thereof, and the recombinant system comprises a recombinase operon 109TES derived from a salmonella Aeromonas phage vB_AsaM-56; the operon comprises at least one gene with exonuclease function and one single-stranded DNA annealing protein gene. Through function verification in Escherichia coli, 109TES can efficiently mediate linear circle recombination and linear linear recombination by using a short homologous arm (50 bp), and has stable and reliable recombination function in a heterologous host, indicating that the recombinase operon from a non-Escherichia coli phage can also exert efficient homologous recombination function in Escherichia coli, and can be used as a powerful candidate for constructing a new type of recombination tool, and provides a new choice for developing a multi-host available gene editing system.

The invention relates to the technical field of preparation of biological agents, and particularly discloses a method for improving the stability and antibacterial persistence of an Escherichia coli bacteriophage preparation. The method comprises the following steps: adding chitosan in a culture process of escherichia coli host bacteria, and inoculating bacteriophage to complete lysis proliferation when the host bacteria are in a logarithmic phase; sequentially carrying out low-shear-force centrifugation, membrane filtration and membrane concentration treatment on the obtained bacteriophage proliferation liquid; adding a compound stabilizer consisting of EDTA (Ethylene Diamine Tetraacetic Acid), glycine, glycerol, trehalose and polyethylene glycol into the concentrated bacteriophage solution for stabilizing treatment; and finally, carrying out multi-stage filtration sterilization to obtain the phage preparation. The coliphage preparation prepared by the method shows good titer retention performance under normal-temperature and low-temperature storage conditions, and has longer effective antibacterial duration. The method is mild in preparation process, high in repeatability and suitable for large-scale preparation.

The invention discloses an aeromonas bacteriophage recombination system, an expression vector, a recombination strain and application of the aeromonas bacteriophage recombination system. The recombination system comprises a recombinase operon 109TES derived from aeromonas salmonicida bacteriophage vBAsaM-56; the operon comprises at least one gene with exonuclease function and a single-stranded DNA annealing protein gene. Through functional verification in Escherichia coli, 109TES can utilize a short homologous arm (50bp) to efficiently mediate wire loop recombination and wire-line recombination, and has a stable and dependable recombination function in a heterologous host, which indicates that a recombinase operon from a non-Escherichia coli bacteriophage can also exert an efficient homologous recombination function in the Escherichia coli, so that the recombinant enzyme operon can be used for preparing a recombinant vector. The method can be used as a powerful candidate for constructing a novel recombination tool, and a new choice is provided for developing a multi-host available gene editing system.

Provided are a phage and a use thereof in preparing a biological formulation for inhibiting drug-resistant bacteria, relating to the field of biomedicine. An Escherichia coli phage Phage vB_EcoM_GZMU_E1004 is isolated from a mixture of lake water and sewage. The phage is deposited under the accession number GDMCC No: 64729-B1, and has the function of significantly inhibiting Escherichia coli. In addition, the combined use of the phage and allicin can further enhance the antibacterial effect against Escherichia coli. The obtained phage can reduce the use of antibiotics, enrich the natural phage resources of drug-resistant Escherichia coli, and provide an important foundation and basis for the phage treatment of drug-resistant Escherichia coli.

This invention proposes an *Escherichia coli* bacteriophage, a bacteriophage composition, its application, and a bacteriophage preparation, relating to the field of microbial technology. The *Escherichia coli* bacteriophage is named *Escherichia coli* bacteriophage GaoM7-14E, with accession number CGMCC NO.46188, deposited on September 20, 2024. Another *Escherichia coli* bacteriophage is named *Escherichia coli* bacteriophage JM3e, with accession number CGMCC NO.46186, deposited on September 18, 2024. The technical solution of this invention uses bacteriophage GaoM7-14E and bacteriophage JM3e as a bacteriophage composition, which can synergistically inhibit *Escherichia coli*, thereby inhibiting pathogenic *Escherichia coli*, and thus preventing and treating *Escherichia coli* diseases.

The invention discloses an Escherichia coli bacteriophage, a bacteriophage composition and application thereof, the Escherichia coli bacteriophage is an Escherichia coli bacteriophage D4 or an Escherichia coli bacteriophage D10, the preservation number of the Escherichia coli bacteriophage D4 is CGMCC NO.46363, the preservation number of the Escherichia coli bacteriophage D10 is CGMCC NO.46366, and the preservation number of the The strain is preserved in China General Microbiological Culture Collection Center (CGMCC) on January 2, 2025, and the preservation address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The bacteriophage composition comprises the escherichia coli bacteriophage and other bacteriophages. The Escherichia coli phage D4 or D10 shows excellent splitting performance on clinically separated multi-drug-resistance Escherichia coli, can be used as an active component independently or in combination with other phages, and is used for preparing environment-friendly biological bactericides, pharmaceutical preparations or disinfectants. The compound is applied to the aspects of sterilization, bacteriostasis and disinfection of multi-drug-resistant escherichia coli, treatment or prevention of infectious diseases caused by escherichia coli and the like.